Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.72 |
| ▸ | PGK1 | P00558 | 1/20 | 0.69 |
| ▸ | PGK2 | P07205 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanosine SCHEMBL608145 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL23927999 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8185769 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL4083505 | 1.00 | CYP2C19 (0.73) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8612570 | 0.99 | CYP2C19 (0.72) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL8612560 | 0.99 | CYP2C19 (0.72) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3861782 | 0.94 | CYP2C19 (0.67) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3294897 | 0.94 | CYP2C19 (0.67) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL11084568 | 0.93 | CYP2C19 (0.69) | CYP2C19SLC29A1ADORA3ADORA1PGK1 | |
| Thioguanosine SCHEMBL3928265 | 0.91 | CYP2C19 (0.62) | CYP2C19SLC29A1ADORA3ADORA1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-6500945-B2 | BIOSYNTHESIS; STEREOSPECIFIC | ISIS PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | COOK PHILLIP DAN (US) | 2002-09-26 | — | — | US | disclosed |
| EP-0655088-B1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. | 2001-07-19 | — | — | US | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137921-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | CYP2C19 4561/4885SLC29A1 219/4885ADORA3 360/4885 |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | CYP2C19 4561/4885SLC29A1 219/4885ADORA3 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.